In recent years, the field of hematologic malignancies has witnessed remarkable breakthroughs, with Chinese researchers making increasingly significant contributions, particularly in cellular therapy. Their work has played a crucial role in advancing both scientific progress and clinical practice. As we step into the new year, Hematology Frontier has invited Dr. Huilai Zhang from Tianjin Medical University Cancer Institute and Hospital to provide an in-depth review of the current landscape and key developments in follicular lymphoma in 2024. This comprehensive analysis aims to offer valuable insights for clinical practice and future research directions.